Zurcher Kantonalbank Zurich Cantonalbank Buys 3,668 Shares of Envista Holdings Co. (NYSE:NVST)

Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Envista Holdings Co. (NYSE:NVST) by 11.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 35,552 shares of the company’s stock after buying an additional 3,668 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Envista were worth $855,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Headinvest LLC acquired a new position in shares of Envista in the third quarter valued at approximately $28,000. Fifth Third Bancorp lifted its holdings in Envista by 98.1% during the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock worth $30,000 after purchasing an additional 621 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in Envista in the 3rd quarter valued at $47,000. Covestor Ltd grew its holdings in Envista by 33.9% in the 3rd quarter. Covestor Ltd now owns 2,462 shares of the company’s stock valued at $69,000 after buying an additional 624 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in Envista by 69.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,516 shares of the company’s stock worth $126,000 after buying an additional 1,844 shares during the period.

Envista Stock Performance

NYSE:NVST opened at $20.39 on Monday. The company has a quick ratio of 1.90, a current ratio of 2.23 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $3.50 billion, a PE ratio of -33.43, a price-to-earnings-growth ratio of 3.81 and a beta of 1.35. Envista Holdings Co. has a twelve month low of $18.95 and a twelve month high of $38.68. The stock’s 50-day simple moving average is $20.95 and its 200 day simple moving average is $22.67.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, February 7th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.04). Envista had a negative net margin of 3.90% and a positive return on equity of 6.31%. The company had revenue of $645.60 million during the quarter, compared to analyst estimates of $638.37 million. During the same quarter in the previous year, the business posted $0.52 earnings per share. The company’s revenue for the quarter was down 2.3% on a year-over-year basis. On average, analysts anticipate that Envista Holdings Co. will post 1.43 EPS for the current fiscal year.

Analysts Set New Price Targets

NVST has been the topic of several research reports. TheStreet downgraded shares of Envista from a “c” rating to a “d+” rating in a research note on Wednesday, February 7th. Leerink Partnrs restated an “underperform” rating on shares of Envista in a research report on Monday, February 26th. Morgan Stanley downgraded shares of Envista from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $33.00 to $21.00 in a research report on Friday. UBS Group started coverage on Envista in a report on Friday, January 5th. They issued a “neutral” rating and a $26.00 price objective for the company. Finally, Jefferies Financial Group cut Envista from a “buy” rating to a “hold” rating and decreased their price target for the stock from $30.00 to $23.00 in a research report on Friday, February 9th. Three analysts have rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $27.90.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.